Adherence to daily HIV pre-exposure prophylaxis in a large-scale implementation study in New South Wales, Australia.
AIDS
; 35(12): 1987-1996, 2021 10 01.
Article
em En
| MEDLINE
| ID: mdl-34101630
ABSTRACT
OBJECTIVES:
To examine patterns of long-term pre-exposure prophylaxis (PrEP) adherence and its association with HIV seroconversion in NSW, Australia.DESIGN:
Population-based HIV PrEP implementation study.METHODS:
Expanded PrEP Implementation in Communities in New South Wales was an open-label study of daily oral PrEP which recruited participants from March 2016 to April 2018. Adherence was measured using dispensing records. PrEP discontinuation was defined as an at least 120-day period without PrEP coverage. Long-term adherence patterns were identified using group-based trajectory modelling.RESULTS:
Participants dispensed at least once (nâ=â9586) were almost all male (98.5%), identified as gay (91.3%), with a median age of 34 years (range 18-86). Of the 6460 (67.4%) participants who had at least 9 months of follow-up since first dispensing, 1942 (30.1%) discontinued. Among these, 292 (15.0%) restarted later. Four distinct groups were identified ['Steep decline' in adherence (15.8%), 'Steady decline' (11.6%), 'Good adherence' (37.4%), and 'Excellent adherence' (35.2%)]. Older (Pâ<â0.001) and gay-identified (Pâ<â0.001) participants were more likely to have higher adherence, so were those living in postcodes with a higher proportion of gay-identified male residents (Pâ<â0.001). Conversely, those who at baseline reported recent crystal methamphetamine use and had a recent diagnosis of sexually transmitted infection (STI) had lower adherence (Pâ<â0.001). Overall HIV incidence was 0.94 per 1000 person-years (95% confidence interval 0.49-1.81; nâ=â9) and was highest in the 'steep decline' group (5.45 per 1000 person-years; Pâ=â0.001).CONCLUSION:
About 15% of participants stopped PrEP during study follow-up and were at increased risk of HIV infection. They were more likely to be younger and report a recent STI or methamphetamine use prior to PrEP initiation.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
Fármacos Anti-HIV
/
Profilaxia Pré-Exposição
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article